|
|
 Previous Article | Table of Contents | Next Article 
Semiquantitative analysis of integrated genomes of human T-lymphotropic
virus type I in asymptomatic virus carriers
O Shinzato, S Ikeda, S Momita, Y Nagata, S Kamihira, E Nakayama and H Shiku
Department of Oncology, Hematology, Nagasaki University School of Medicine,
Japan.
A semiquantitative estimation of human T-lymphotropic virus type I (HTLV-I)
integration by peripheral blood mononuclear cells (PBMC) was performed.
Genomic DNA samples derived from 134 HTLV-I carriers were subjected to 40
or 60 cycles of the polymerase chain reaction to amplify the pol region of
HTLV-I. The HTLV-I genome was detected by dot hybridization using a
32P-labeled oligonucleotide probe for the pol region. The radioactivity of
hybridized dot membranes was then counted with an RI Imaging System (Ambis
Inc, San Diego, CA) and the HTLV-I genome dose was determined by comparison
with standard curve for serially diluted HTLV-I genome-positive DNA. A wide
range of variation of HTLV-I genome integration was observed. When the
integrated genome dose was calculated as the number of HTLV-I copies per
100 PBMC, 7 carriers (5%) had more than 10 copies, 56 (42%) had 1 to 10
copies, 46 (34%) had 0.1 to 1 copy, and 24 (18%) had less than 0.1 copy. In
one sample, the HTLV-I genome was undetectable, which may indicate that the
integrated genome was present at less than 0.01 copies per 100 PBMC. Age-
or sex-related variations in the distribution of individuals with different
HTLV-I genome were rather limited. However, carriers with a high level of
the HTLV-I genome were always more than 30 years old and were predominantly
male (six of seven).
Volume 78,
Issue 8,
pp. 2082-2088,
10/15/1991
Copyright © 1991 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. R. Silverman, A. J. Phipps, A. Montgomery, S. Fernandez, T. Tsukahara, L. Ratner, and M. D. Lairmore
In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations
Blood,
November 15, 2005;
106(10):
3602 - 3608.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Imaizumi, M. Iwanaga, K. Tsukasaki, T. Hata, M. Tomonaga, and S. Ikeda
Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes ("pre-ATL") in a 20-year follow-up study
Blood,
January 15, 2005;
105(2):
903 - 904.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Wenz, G. A. Ortolano, J.-P. Allain, and L. M. Williamson
Leukocyte reduction and HTLV-I: is the glass half empty or half full?
Blood,
January 1, 2003;
101(1):
370 - 370.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mortreux, M. Kazanji, A.-S. Gabet, B. de Thoisy, and E. Wattel
Two-Step Nature of Human T-Cell Leukemia Virus Type 1 Replication in Experimentally Infected Squirrel Monkeys (Saimiri sciureus)
J. Virol.,
January 15, 2001;
75(2):
1083 - 1089.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J.H. Richardson, P. Hollsberg, A. Windhagen, L.A. Child, D.A. Hafler, and A.M.L. Lever
Variable Immortalizing Potential and Frequent Virus Latency in Blood-Derived T-Cell Clones Infected With Human T-Cell Leukemia Virus Type I
Blood,
May 1, 1997;
89(9):
3303 - 3314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
